Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146

Benzinga · 1d ago
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.